Literature DB >> 16355319

Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.

L Clifford McDonald1.   

Abstract

Antimicrobial resistance in health care-associated pathogens is a growing concern for health care and for public health. A recent shift in the epidemiological profile of methicillin-resistant Staphylococcus aureus has resulted not only in health care-associated infections but now, also, in community-associated infections. Reports have described S. aureus exhibiting decreased susceptibility and, even, resistance to vancomycin. The rate of vancomycin resistance among enterococci may be leveling; however, vancomycin resistance in Enterococcus faecium has already achieved high levels. Multidrug resistance in Pseudomonas aeruginosa is increasing, and carbapenem-resistant Klebsiella strains are emerging. Acinetobacter species cause a minority of health care-associated pneumonias due to gram-negative organisms, but a growing proportion is resistant to carbapenems and third-generation cephalosporins. Recent increases in the frequency and severity of Clostridium difficile-associated illness are associated with the emergence of a hypervirulent C. difficile strain with increased resistance to the fluoroquinolones. The presence of these and other resistant organisms in health care facilities limits the number of effective antimicrobials available for treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16355319     DOI: 10.1086/499404

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  Detection of methicillin-resistant Staphylococcus aureus (MRSA) from nasal samples by multiplex real-time PCR based on dual priming AT-rich primers.

Authors:  M K Yadav; S K Kwon; H J Huh; S-W Chae; J-J Song
Journal:  Folia Microbiol (Praha)       Date:  2011-12-22       Impact factor: 2.099

2.  Multidrug-resistant organisms, wounds and topical antimicrobial protection.

Authors:  Philip G Bowler; Sarah Welsby; Victoria Towers; Rebecca Booth; Andrea Hogarth; Victoria Rowlands; Alexis Joseph; Samantha A Jones
Journal:  Int Wound J       Date:  2012-05-29       Impact factor: 3.315

3.  Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration.

Authors:  Erika M C D'Agata; Pierre Magal; Damien Olivier; Shigui Ruan; Glenn F Webb
Journal:  J Theor Biol       Date:  2007-08-25       Impact factor: 2.691

4.  Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model.

Authors:  Kyros Ipaktchi; Aladdein Mattar; Andreas D Niederbichler; Laszlo M Hoesel; Sabrina Vollmannshauser; Mark R Hemmila; Rebecca M Minter; Grace L Su; Stewart C Wang; Saman Arbabi
Journal:  Surgery       Date:  2007-07       Impact factor: 3.982

Review 5.  A clinical review of infected wound treatment with Vacuum Assisted Closure (V.A.C.) therapy: experience and case series.

Authors:  Allen Gabriel; Jaimie Shores; Brent Bernstein; Jean de Leon; Ravi Kamepalli; Tom Wolvos; Mona M Baharestani; Subhas Gupta
Journal:  Int Wound J       Date:  2009-10       Impact factor: 3.315

6.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

7.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.

Authors:  Kristy N Katzenmeyer; Luisa M Szott; James D Bryers
Journal:  Pathog Dis       Date:  2017-08-31       Impact factor: 3.166

9.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

10.  What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?

Authors:  Caroline Colijn; Ted Cohen; Christophe Fraser; William Hanage; Edward Goldstein; Noga Givon-Lavi; Ron Dagan; Marc Lipsitch
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.